Published in Mol Cancer Ther on September 15, 2009
Discovery of nonsteroidal anti-inflammatory drug and anticancer drug enhancing reprogramming and induced pluripotent stem cell generation. Stem Cells (2011) 1.08
Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. J Lipid Res (2013) 0.80
Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPARγ-dependent pathway. Oncotarget (2016) 0.80
Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer. Lung Cancer (Auckl) (2011) 0.75
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell (2003) 2.71
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst (2006) 2.51
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther (2003) 2.24
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst (2004) 2.13
Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev (2001) 2.09
Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res (1997) 1.96
Cyclooxygenases in cancer: progress and perspective. Cancer Lett (2004) 1.74
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res (2005) 1.46
Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene (1999) 1.41
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther (2007) 1.33
Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control (2002) 1.31
COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J (2003) 1.24
Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. Clin Exp Metastasis (2006) 1.19
Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism. J Biol Chem (1999) 1.18
Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J (2001) 1.18
Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res (2002) 1.14
Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther (2006) 1.10
Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr Med Chem Anticancer Agents (2003) 1.07
Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene (2006) 1.06
D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer (1997) 1.06
Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res (2002) 1.05
In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res (2004) 1.04
Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis (2007) 1.02
Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res (2006) 1.00
Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol Cancer Ther (2006) 0.99
Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway. J Biol Chem (2000) 0.98
Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood (2005) 0.95
Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology (2005) 0.94
Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys (2001) 0.93
Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells. Oncogene (2007) 0.88
Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs (2007) 0.87
Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol Pharmacol (2004) 0.87
ET-18-O-CH3-induced apoptosis is causally linked to COX-2 upregulation in H-ras transformed human breast epithelial cells. FEBS Lett (2005) 0.79
Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer (2005) 0.79
Induction of cyclooxygenase-2 in Ras-transformed human mammary epithelial cells undergoing apoptosis. Ann N Y Acad Sci (2002) 0.77
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell (2011) 2.61
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res (2005) 2.43
Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin (2011) 2.42
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
Translation of innovative designs into phase I trials. J Clin Oncol (2007) 2.30
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst (2004) 2.13
Head and neck cancer chemoprevention gets a shot in the arm. J Clin Oncol (2008) 2.09
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res (2008) 2.01
Perspectives for cancer prevention with natural compounds. J Clin Oncol (2009) 1.99
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res (2006) 1.94
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer (2012) 1.94
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res (2006) 1.85
Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol (2006) 1.78
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther (2007) 1.71
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res (2005) 1.70
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res (2009) 1.70
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol (2007) 1.54
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol (2013) 1.54
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) (2011) 1.53
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest (2010) 1.50
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol (2002) 1.50
Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci U S A (2007) 1.49
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer (2004) 1.47
Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. Cancer Biol Ther (2005) 1.47
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol (2008) 1.43
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol (2011) 1.42
Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther (2007) 1.41
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem (2010) 1.40
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control (2003) 1.39
14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol (2011) 1.38
Accurate biopsy of bile duct without destroying duodenal papilla. Turk J Gastroenterol (2016) 1.37
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther (2008) 1.36
Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res (2011) 1.36
Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. Cancer (2012) 1.33
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther (2007) 1.33
Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res (2004) 1.32
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 1.32
Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol (2007) 1.31
p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res (2004) 1.30
The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem (2009) 1.30
2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther (2008) 1.29
Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci (2013) 1.29
LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res (2008) 1.28
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res (2005) 1.28
Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). Cancer Biol Ther (2006) 1.27
A novel DNMT3B subfamily, DeltaDNMT3B, is the predominant form of DNMT3B in non-small cell lung cancer. Int J Oncol (2006) 1.27
Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res (2002) 1.26
Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res (2002) 1.26
The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res (2008) 1.26
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol (2004) 1.25
Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res (2008) 1.25